NEJM This Week NEJM This Week — June 19, 2025
11 snips
Jun 18, 2025 The discussion covers groundbreaking treatments for mismatch repair-deficient tumors and HER2-mutant lung cancer. An urgent Corynebacterium diphtheriae outbreak is highlighted, alongside insights into hereditary kidney cancers. The risks and management of unruptured intracranial aneurysms are explored, featuring a case study on post-kidney transplant complications. The impact of AI on clinician autonomy raises thought-provoking concerns. Finally, emotional challenges faced by healthcare professionals, particularly in high-pressure environments like NICUs, are poignantly examined.
AI Snips
Chapters
Transcript
Episode notes
PD-1 Blockade Preserves Organs
- Neoadjuvant PD-1 blockade led to organ preservation in a high proportion of patients with mismatch repair deficient tumors.
- This approach could potentially extend beyond rectal cancer to other DMMR solid tumors with further evidence.
New Myasthenia Gravis Treatment
- Inebuilizumab reduces symptoms in generalized myasthenia gravis by depleting CD19 B cells.
- Its infrequent administration may improve adherence and offer cost advantages over other treatments.
Zongertinib Effective in Lung Cancer
- Zongertinib showed a 71% objective response rate in HER2 mutant non-small cell lung cancer.
- The drug's mainly low-grade adverse events make it a promising oral targeted therapy.